Apalutamide product info, just an FYI - Advanced Prostate...

Advanced Prostate Cancer

21,447 members26,867 posts

Apalutamide product info, just an FYI

Darryl profile image
DarrylPartner
4 Replies

I got an email with the following regarding Apalutamide, so I thought to post and share.

MECHANISM OF ACTIONApalutamide is a second generation androgen receptor inhibitor

INDICATIONApalutamide indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

STUDY DESIGN & POPULATIONA global randomized double-blind, placebo-controlled Phase III trial (n=1,207) evaluating Apalutamide vs. placebo in nmCRPC patients at high risk for developing metastases (as defined by PSA doubling-time of ≤10 months and PSA above 2ng/mL):

No prior chemotherapy, immunotherapy, second generation AR antagonist, or CYP17A inhibitor

Ongoing androgen deprivation therapy (ADT) or prior orchiectomy

ECOG 0 or 1

M0 is determined by using bone scan, MRI, and/or CT

DOSING & ADMINISTRATIONApalutamide capsules x 4, administered once daily

PRIMARY ENDPOINTMetastasis-free survival (MFS): 40.5 months for apalutamide vs. 16 months for placebo (increase of 24 months); HR 0.28, p < 0.0001)

OS SECONDARY ENDPOINTOverall survival (OS) data were not mature at the time of final MFS analysis but show a positive trend in OS improvement for apalutamide vs placebo

OTHER SECONDARY EFFICACY ENDPOINTSStatistically significant improvement in time to metastases, progression-free survival, and time to symptomatic progression.

QUALITY OF LIFENo difference between apalutamide and placebo in the time to deterioration in health-related QOL measured by FACT-P and EQ-5D

SAFETYIncidence of All AEs (Apalutamide vs. placebo)

Diarrhea: 20% vs 15%

Nausea: 18% vs 15.8%

Rash: 23.8% vs 5.5%

Fracture: 11.7% vs 6.5%

Hypertension: 24.8% vs 19.8%

Dizziness: 9.3% vs 6.3%

Fall: 15.6% vs 9.0%

Fatigue: 30.4% vs 21.1%

Seizures/convulsions: 0.2% (2 pts.) vs 0%

Mental impairment: 5.1% vs 3.0%

Additional DataIncreased incidence of seizures stated in the Prescribing Information Warning & Precautions section.

Written by
Darryl profile image
Darryl
Partner
To view profiles and participate in discussions please or .
Read more about...
4 Replies

Again, thanks for this post Darryl.

lakersfan profile image
lakersfan

Hi Darryl, thanks for the post. I'm trying to learn a bit about the marketing of drugs for PC. Was this email straight from the manufacturer, or some 3rd party? Also, is this United States-based, or coming from a different country. Thanks for the help!

Darryl profile image
DarrylPartner in reply to lakersfan

Hi I received the email over three months ago...I'm sorry not to have answers to your questions.

lakersfan profile image
lakersfan in reply to Darryl

It's ok, thanks for the quick response!

You may also like...

Enzalutamide Product info, FYI

in nmCRPC patients at high risk for developing metastases (as defined by PSA doubling-time of ≤10...

Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

progression–free survival at 24 months was 68.2% in the apalutamide group and 47.5% in the placebo...

Apalutamide - SPARTAN versus Enzalutamide - PROSPER.

median metastasis-free survival (MFS) of 40.5 months versus 16.2 months for placebo treatment.\\"...

How Long Does the FDA’s Real-Time Oncology Review Program Take to Approve New Drug Applications?

radiographic progression-free survival (rPFS) and overall survival (OS) compared with placebo and...

EMBARK trial results reported

improvement in MFS [Metastases free survival] for patients treated with XTANDI monotherapy versus...